Looking for novel, brain-derived, peripheral biomarkers of neurological disorders

Chmielewska, Natalia; Szyndler, Janusz; Makowska, Karolina; Wojtyna, Dawid; Maciejak, Piotr; Płaźnik, Adam

doi:10.1016/j.pjnns.2018.02.002

Cited by 39 publications

(38 citation statements)

References 83 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple sclerosis (MS) is a progressive, chronic, autoimmune inflammatory and degenerative process that damages CSN. MS is characteristic for patients with the presence of plaques and lesions in the brain and spinal cord, primarily the white matter of the brain [3,7,85,86]. The mechanism of MS development remains poorly understood.…”

Section: Multiple Sclerosismentioning

confidence: 99%

The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke

et al. 2020

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that plays a crucial role in the development of the nervous system while supporting the survival of existing neurons and instigating neurogenesis. Altered levels of BDNF, both in the circulation and in the central nervous system (CNS), have been reported to be involved in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), multiple sclerosis (MS), and ischemic stroke. MicroRNAs (miRNAs) are a class of non-coding RNAs found in body fluids such as peripheral blood and cerebrospinal fluid. Several different miRNAs, and their target genes, are recognized to be involved in the pathophysiology of neurodegenerative and neurovascular diseases. Thus, they present as promising biomarkers and a novel treatment approach for CNS disorders. Currently, limited studies provide viable evidence of miRNA-mediated post-transcriptional regulation of BDNF. The aim of this review is to provide a comprehensive assessment of the current knowledge regarding the potential diagnostic and prognostic values of miRNAs affecting BDNF expression and its role as a CNS disorders and neurovascular disease biomarker. Moreover, a novel therapeutic approach in neurodegenerative diseases and ischemic stroke targeting miRNAs associated with BDNF will be discussed.

show abstract

Section: Multiple Sclerosismentioning

confidence: 99%

The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Increased BBB permeability can have deleterious effects on the brain by pro-inflammatory cells and molecules entering in brain (79). Although, there is no concensus regarding the best way to monitor increased BBB permeability in patients with schizophrenia, several novel candidates including matrix metalloproteinase-9(MMP-9), ubiquitin carboxy-terminal hydrolase-L1(UCHL-L1), neurofilaments, brain derived neurotropic factor (BDNF), miRNA in addition to S100B and glial fibrillary acidic protein (GFAP) are available for future studies, and preferably aggregated and applied in panels of several biomarkers (86).…”

Section: Dysregulated Immune System and Inflammation In Schizophreniamentioning

confidence: 99%

“…This can only be done in large longitudinal studies where multiple markers are monitored and predictors for increased symptoms, decreased function and other adverse developments are identified. Currently, biomarker panels are preferred to single markers (86), and individual differences must be accounted for (11).…”

Section: Constructing the Inflammatory Signature Of Schizophrenia Formentioning

confidence: 99%

Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics

et al. 2019

View full text Add to dashboard Cite

Schizophrenia is considered a syndrome comprised by several disease phenotypes, covering a range of underlying pathologies. One of these disease mechanisms seems to involve immune dysregulation and neuroinflammation. While the current dopamine receptor-blocking antipsychotic drugs decrease psychotic symptoms and prevent relapse in the majority of patients with schizophrenia, there is a huge need to explore new treatment options that target other pathophysiological pathways. Such studies should aim at identifying robust biomarkers in order to diagnose and monitor the immune biophenotype in schizophrenia and develop better selection procedures for clinical trials with anti-inflammatory and immune-modulating drugs. In this focused review, we describe available methods to assess inflammatory status and immune disturbances in vivo. We also outline findings of immune disturbances and signs of inflammation at cellular, protein, and brain imaging levels in patients with schizophrenia. Furthermore, we summarize the results from studies with anti-inflammatory or other immune-modulating drugs, highlighting how such studies have dealt with participant selection. Finally, we propose a strategy to construct an immune signature that may be helpful in selecting and monitoring participants in studies with immune modulating drugs and also applicable in regular clinical work.

show abstract

“…[48] However, the specificity is poor since MMP-9 is also increased in a variety of diseases, such as cancer, heart diseases, diabetes, epilepsy, and neurodegenerative diseases. [68697071]…”

Section: Introductionmentioning

confidence: 99%

Current progress in searching for clinically useful biomarkers of blood–brain barrier damage following cerebral ischemia

Pan

et al. 2018

Brain Circ

View full text Add to dashboard Cite

Ischemic stroke is a leading cause of death and disability. Fear of intracranial hemorrhage (ICH) has been the primary reason for withholding tissue plasminogen activator (tPA) and thrombectomy, the only two widely accepted treatments for ischemic stroke. Thrombolysis treatment is only allowed in a very narrow time window (within 4.5–6 h). However, so far, other than the time window guideline, there is no reliable indicator available in the clinic to predict ICH before thrombolysis treatment. Recently, extensive research efforts have been devoted to the development of reliable indicators to predict ICH and safely guide the thrombolysis treatment. Accumulating evidence suggests that ischemic brain regions with a compromised blood–brain barrier (BBB) before tPA treatment develop ICH at the later time during thrombolytic reperfusion. Assessing BBB damage before thrombolysis could potentially help predict the risk of ICH after thrombolysis. This article reviews the literature reports on BBB damage biomarkers that have been developed in recent years, including biochemical markers such as BBB structural proteins, circulating brain microvascular endothelial cells, plasma albumin, and brain parenchyma proteins, as well as image markers such as magnetic resonance imaging assessment for BBB damage.

show abstract

Looking for novel, brain-derived, peripheral biomarkers of neurological disorders

Cited by 39 publications

References 83 publications

The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke

The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke

Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics

Current progress in searching for clinically useful biomarkers of blood–brain barrier damage following cerebral ischemia

Contact Info

Product

Resources

About